One of the UK’s largest initiatives for combating antimicrobial resistance, Pathways to Antimicrobial Clinical Efficacy (Pace), has announced up to £6 million in funding to drive new research. This support aims to accelerate the development of novel therapies for serious bacterial infections.
This latest funding round reflects our commitment to supporting the most innovative global research in antimicrobial resistance (AMR), said Beverley Isherwood, programme director of Pace. “We’re excited that we can now support even more pioneering projects that have the potential to save lives and protect future generations from drug-resistant infections.”
This is the third Pace funding round dedicated to innovative therapeutic projects. The initiative focuses on accelerating early-stage drug and diagnostic development targeting resistant bacterial infections that pose the highest global health burden.
The call is designed to fill a critical gap in the fight against antimicrobial resistance and to foster advancements that could transform treatment options worldwide.
https://sciencebusiness.net/news/r-d-funding/antimicrobial-resistance/funding-radar-uk-and-eu-bring-forward-antimicrobial-resistance
